drugset / Trial / NCT05970666
Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma
Phase 2
Recruiting
71 enrolled
The First Affiliated Hospital of Xiamen University
Jiangsu HengRui Medicine Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of TACE combined with adebrelimab and bevacizumab transformation in unresectable hepatocellular carcinoma
Timeline
- Start
- 2023-11-15
- Primary completion
- 2026-11-15
- Completion
- 2026-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | 20 mg/kg | — |
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | — |